Estrella Immunopharma annual return on equity
2024
Estrella Immunopharma Return on Equity (ROE) Growth & History (ESLA)
Estrella Immunopharma's return on equity was −200.44% for fiscal 2024.
View full Estrella Immunopharma company overviewEstrella Immunopharma annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2024 · Dec 31 | 2024-12-31 | −200.44% | — |
Estrella Immunopharma quarterly return on equity
Q2.24
Q3.24
Q4.24
Q1.25
Q4.24
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q4 2024 | 2024-12-31 | 757.36% | +768.04 pp |
| Q1 2025 · Sep 30 | 2024-09-30 | −134.54% | — |
| Q4 2024 | 2024-06-30 | −61.89% | — |
| Q3 2024 | 2024-03-31 | −5.35% | — |
| Q2 2024 | 2023-12-31 | −10.68% | — |
Estrella Immunopharma return on equity trends
The latest reported quarter, Q4 2024, shows 757.36%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Estrella Immunopharma source filings ↗